Screener
Veradermics MANE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Veradermics’s 10-K, filed March 30, 2026.
- Filed
- Mar 30, 2026, 5:35 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001827635-26-000013
| (in thousands, except share and per share amounts) | As of December 31, 2025 | As of December 31, 2024 |
|---|---|---|
| Series C preferred stock, $0.00001 par value, 118,682,683 shares authorized, issued and outstanding with an aggregate liquidation preference of $154,815 as of December 31, 2025 net of issuance costs | 150,563 | — |
| Subscription receivable | (1,849) | (3,848) |
| Stockholders’ equity (deficit) | ||
| Common stock, $0.00001 par value, 267,466,797 and 98,774,582 shares authorized as of December 31, 2025 and 2024, respectively and 749,760 and 736,933 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1 | 1 |
| Additional paid-in capital | 2,346 | 750 |
| Accumulated other comprehensive income | 60 | — |
| Accumulated deficit | (123,421) | (49,231) |
| Total stockholders’ deficit | (121,014) | (48,480) |
Item 16. Form 10-K Summary
FAQ
- What is Veradermics's common stock?
- Veradermics (MANE) reported common stock of $1K in Q4 2025.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Veradermics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude